AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$PMVP

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate

PMV Pharmaceuticals, Inc. (PMVP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights • Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed • Rez

Original reporting
SEC EDGAR 8-K
Published Aug 14, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 12:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PMVP
Bullish
medium confidence
Mentioned
$PMVP
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PMVPBullishMed
01

Why it matters

The filing updates both the financial baseline (cash and burn) and a key development milestone (Phase 2 monotherapy enrollment completion) plus a concrete next regulatory step (NDA submission planned for first quarter 2027).

02

Market read

Traders can update probability-weighted expectations for an accelerated-approval NDA timeline and assess near-term liquidity risk based on updated cash and operating loss trends.

03

What to watch

Cash fell from $112.9M (Dec 31, 2025) to $79.4M (Jun 30, 2026), so runway through Q2 2027 may still require financing if development costs or timelines slip.

Relevance 7/10Novelty 7/10Timing: today’s SEC 8-K, with Q1 2027 NDA timing guidance

Background

This is an SEC Form 8-K with Exhibit 99.1 covering PMV Pharma’s Q2 2026 financial results and clinical/regulatory corporate update for rezatapopt in the PYNNACLE trial.

Company-level read

Ticker impact

$PMVPBullishMedium confidence
Context

PMV Pharma reports Q2 2026 results and says PYNNACLE Phase 2 monotherapy enrollment is complete, with an rezatapopt NDA planned for Q1 2027.

Expected impact

Likely positive bias for PMVP as traders price forward NDA timing and trial progress, tempered by cash burn and clinical-stage risk.

Evidence & confidence

The filing provides concrete operational milestones (enrollment completion) and a specific future regulatory action window (first quarter 2027), plus updated liquidity ($79.4M at June 30, 2026).

Market effects

Sector

Adds incremental signal for p53 reactivator development and TP53 Y220C targeted oncology, but limited direct read-across to broader biotech beyond precision oncology sentiment.

Regional

Primarily US small-cap biotech sentiment; no specific regional macro linkage in the filing.

Global

Global investors may reassess timelines for targeted oncology programs, but the disclosure is company-specific and not a cross-border regulatory event.

Counterpoint

What could challenge this read

Enrollment completion does not guarantee efficacy or regulatory acceptance; the market may overreact to timeline language while ignoring probability-weighted clinical outcomes.

Key entities

  • company
    PMV Pharmaceuticals, Inc.

    Nasdaq-listed precision oncology company developing rezatapopt (PC14586) targeting p53 Y220C mutations.

  • product_candidate
    Rezatapopt (PC14586)

    First-in-class p53 reactivator designed to selectively bind the pocket in p53 Y220C mutant protein.

  • clinical_program
    PYNNACLE clinical trial

    Ongoing Phase 1/2 trial evaluating rezatapopt in TP53 Y220C advanced solid tumors; Phase 2 is registrational, single arm.

  • regulatory_status
    FDA Fast Track and Orphan Drug Designation

    FDA granted Fast Track designation and Orphan Drug Designation for rezatapopt in relevant indications.

Read at source← All news

Related articles

$PMVPMed

PMV Pharmaceuticals 3Q 2026: EPS ($0.52) — 10-Q Summary

PMV Pharmaceuticals reported a wider net loss of $34.37M in Q3 2026, with EPS at ($0.52), due to warrant remeasurement loss and offering costs. The company completed enrollment for a Phase 2 trial of rezatapopt and plans to submit an NDA in Q1 2027. Cash reserves totaled $108.5M, expected to last into Q1 2028.

tradingview.com
$PMVPMedAI 8/10

PMV Pharmaceuticals Reports Q3 2026 Results, $108.5M in Cash and Securities

PMV Pharmaceuticals reported a Q3 2026 net loss of $34.4M, with $108.5M in cash. It expects cash to last into Q1 2028. The company completed enrollment for its Phase 2 ovarian cancer trial and plans to submit a rezatapopt NDA in Q1 2027. Research and development expenses were $16.1M, with general and administrative expenses at $4.0M. The company appointed new board members and a chief commercial officer.

tradingview.com
$PMVPMed

PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate

PMV Pharmaceuticals, Inc. (PMVP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights • Pivotal Phase 2 rezatapopt PYNNACLE data to be featured in late-breaking oral presentation at ENA 2026 • Announced closing of oversubscribed $50 million public offering of sec

SEC EDGAR 8-K
$PMVPMed

PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

PMV Pharmaceuticals (Nasdaq: PMVP) reported Q2 2026 results and clinical updates. Enrollment for the Phase 2 monotherapy primary analysis in its PYNNACLE trial for rezatapopt in TP53 Y220C ovarian cancer is complete. The company plans an NDA for accelerated approval in Q1 2027. Cash, cash equivalents and marketable securities were $79.4M at June 30, 2026, with net loss $18.1M.

finanznachrichten.de